drugset / Trial / NCT04230148
Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).
NaSingle-groupOpen-labelTreatment
Summary
The study evaluated safety and tolerability along with clinical outcomes of Egaten administered as per the FDA approved dosing regimen of 2 doses of 10 mg/kg (given approximately 12 hours apart) in Fascioliasis participants (≥ 6 years of age).
Timeline
- Start
- 2022-02-11
- Primary completion
- 2026-03-27
- Completion
- 2026-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triclabendazole | Small molecule | 10 mg/kg | Oral |